Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Anlon Healthcare
Quarter-by-quarter operating performance
| Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|
| Sales + | 37.83 | 24.17 | 9.36 | 33.30 | 52.20 | 35.58 |
| Expenses + | 30.98 | 16.65 | 8.78 | 27.06 | 38.46 | 23.23 |
| Operating Profit | 6.85 | 7.52 | 0.58 | 6.24 | 13.74 | 12.35 |
| OPM % | 18.11% | 31.11% | 6.20% | 18.74% | 26.32% | 34.71% |
| Other Income + | 0.06 | 0.05 | 0.02 | 0.01 | 0.03 | 0.20 |
| Interest | 0.98 | 0.93 | 0.89 | 0.82 | 0.87 | 1.58 |
| Depreciation | 0.47 | 0.47 | 0.00 | 0.43 | 0.45 | 0.35 |
| Profit before tax | 5.46 | 6.17 | -0.29 | 5.00 | 12.45 | 10.62 |
| Tax % | 16.85% | 57.86% | 758.62% | 29.20% | 25.14% | 51.41% |
| Net Profit + | 4.54 | 2.59 | -2.49 | 3.55 | 9.32 | 5.15 |
| EPS in Rs | 0.28 | 0.06 | -0.06 | 0.09 | 0.18 | 0.10 |
Financials of Anlon Healthcare
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales + | 16 | 57 | 113 | 66 | 120 |
| Expenses + | 21 | 52 | 100 | 51 | 88 |
| Operating Profit | -5 | 6 | 13 | 16 | 33 |
| OPM % | -32% | 10% | 11% | 24% | 27% |
| Other Income + | 0 | 0 | 0 | 0 | 0 |
| Interest | 3 | 4 | 4 | 4 | 4 |
| Depreciation | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | -10 | -0 | 7 | 10 | 27 |
| Tax % | 3% | 0% | 17% | 1% | 24% |
| Net Profit + | -10 | -0 | 6 | 10 | 21 |
| EPS in Rs | -0.85 | -0.01 | 0.48 | 0.60 | 0.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Anlon Healthcare
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 16 | 40 | 53 |
| Reserves | -10 | -10 | -5 | 5 | 41 | 161 |
| Borrowings + | 54 | 62 | 70 | 81 | 67 | 58 |
| Other Liabilities + | 16 | 21 | 34 | 26 | 34 | 37 |
| Total Liabilities | 71 | 85 | 112 | 128 | 181 | 309 |
| Fixed Assets + | 29 | 27 | 26 | 27 | 23 | 22 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 2 | 4 | 1 | 1 | 18 |
| Other Assets + | 43 | 56 | 82 | 100 | 158 | 269 |
| Total Assets | 71 | 85 | 112 | 128 | 181 | 309 |
Financials of Anlon Healthcare
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | -15 | -2 | -3 | -3 | -23 |
| Cash from Investing Activity + | -2 | -0 | -0 | -3 | 3 |
| Cash from Financing Activity + | 16 | 3 | 2 | 8 | 19 |
| Net Cash Flow | -2 | 1 | -1 | 2 | -1 |
| Free Cash Flow | -15 | -2 | -3 | -7 | -20 |
| CFO/OP | 291% | -32% | -23% | -21% | -66% |
Financials of Anlon Healthcare
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 132 | 130 | 142 | 213 | 228 |
| Inventory Days | 669 | 225 | 112 | 452 | 246 |
| Days Payable | 409 | 128 | 105 | 217 | 96 |
| Cash Conversion Cycle | 392 | 226 | 149 | 448 | 377 |
| Working Capital Days | 185 | 163 | 122 | 261 | 292 |
| ROCE % | 7% | 15% | 15% | 25% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…